Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 20
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Xiong Xie, Qiaoshuai Lan, Jinyi Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Utility of PBPK Modeling in Predicting and Characterizing Clinical Drug Interactions
R. Foti
Drug Metabolism and Disposition (2024) Vol. 53, Iss. 1, pp. 100021-100021
Open Access | Times Cited: 6
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 6
A multiplex method for rapidly identifying viral protease inhibitors
Seo Jung Hong, Samuel J. Resnick, Sho Iketani, et al.
Molecular Systems Biology (2025)
Closed Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Rahul K. Suryawanshi, Priyadarshini Jaishankar, G.J. Correy, et al.
(2025)
Open Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Rahul K. Suryawanshi, Priyadarshini Jaishankar, G.J. Correy, et al.
(2025)
Open Access
Membrane-Active Singlet Oxygen Photogenerators as a Paradigm for Broad-Spectrum Antivirals: The Case of Halogenated (BOron)-DIPYrromethenes
Xenia A. Maryewski, Maxim S. Krasilnikov, Petra Straková, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
In Vitro Antiviral Assays: A Review of Laboratory Methods
Gabriel Atampugbire, Eureka Adomako, Osbourne Quaye
Assay and Drug Development Technologies (2025)
Closed Access
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access
Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches
Ayyaz Khan, Zakirullah, Shahid Wahab, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 5
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 5
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1
Ahmed Magdy Khalil, Aitor Nogales, Luis Martínez‐Sobrido, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 4
Targeting histone deacetylases: Emerging applications beyond cancer
Yasir S. Raouf
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104094-104094
Closed Access | Times Cited: 4
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 11
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
Jimena Pérez‐Vargas, Gabriel Lemieux, Connor A.H. Thompson, et al.
Antiviral Research (2024) Vol. 225, pp. 105869-105869
Open Access | Times Cited: 3
Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
Science Advances (2024) Vol. 10, Iss. 35
Open Access | Times Cited: 3
Multiplexed multicolor antiviral assay amenable for high-throughput research
Li-Hsin Li, Winston Chiu, Yun‐An Huang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
A RaPID Response to SARS‐CoV‐2
Sven Ullrich, Christoph Nitsche
Israel Journal of Chemistry (2024)
Open Access | Times Cited: 2
Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning
K. Eurídice Juárez‐Mercado, Milton Abraham Gómez-Hernández, Juana Salinas-Trujano, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 240-240
Open Access | Times Cited: 2
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Tianyang Mao, Joo‐Young Kim, Mario A. Peña-Hernández, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 18
Open Access | Times Cited: 2
Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity
Christian Gege, Friedrich Hahn, Christina Wangen, et al.
ChemMedChem (2024) Vol. 19, Iss. 19
Open Access | Times Cited: 2
Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants
Adrían V. Hernández, Anna Liu, Yuani M. Roman, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107248-107248
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top